Research Analysts Offer Predictions for Genmab A/S’s Q3 2018 Earnings (GNMSF)

Genmab A/S (OTCMKTS:GNMSF) – Research analysts at Jefferies Financial Group cut their Q3 2018 earnings estimates for shares of Genmab A/S in a note issued to investors on Thursday, August 9th. Jefferies Financial Group analyst P. Welford now forecasts that the company will post earnings of $0.63 per share for the quarter, down from their prior estimate of $0.67. Jefferies Financial Group also issued estimates for Genmab A/S’s Q4 2018 earnings at $1.62 EPS, FY2019 earnings at $5.00 EPS, FY2020 earnings at $8.49 EPS, FY2021 earnings at $9.84 EPS and FY2022 earnings at $12.18 EPS.

Several other brokerages have also commented on GNMSF. Zacks Investment Research lowered shares of Genmab A/S from a “hold” rating to a “sell” rating in a report on Friday, May 11th. ValuEngine downgraded shares of Genmab A/S from a “hold” rating to a “sell” rating in a research report on Saturday, May 26th.

Shares of OTCMKTS GNMSF opened at $165.00 on Monday. Genmab A/S has a 12 month low of $143.75 and a 12 month high of $239.75. The firm has a market capitalization of $10.04 billion, a price-to-earnings ratio of 61.11 and a beta of 0.33.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Featured Story: How are Outstanding Shares Different from Authorized Shares?

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply